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Abstract
Background/Aim: Substances in the middle molecular
weight range have been shown to play a significant
pathogenetic role in as diverse disorders as end-stage
renal disease and multiple organ failure. To overcome
the limitations in the amount removed by hemofilters,
new sorbents with a high biocompatibility are actively
being developed. Furthermore, biocompatible sorbents
by their nonspecific adsorptive behavior could have
great impact on detoxification treatment in exogenous
intoxications. We performed an in vitro evaluation of a
newly developed highly biocompatible sorbent cartridge
(Betasorb®), examining its adsorptive capacity concern-
ing therapeutic drugs. Methods: Uremic blood spiked
with a range of therapeutic drugs was recirculated for 2 h
in an in vitro hemoperfusion circuit containing a Beta-
sorb device for hemoperfusion. The drug concentrations
before and after the passage of the cartridge were mea-
sured, and the total amount removed was calculated.
Results: The sorbent showed effective removal of glyco-
peptide antibiotics, digoxin, theophylline, phenobarbital,
phenytoin, carbamazepine, and valproic acid. Moderate
removal could be demonstrated for tacrolimus and cy-
closporine A; aminoglycosides were removed to a small
extent only. Conclusions: Betasorb hemoperfusion
shows a potent adsorptive capacity concerning thera-
peutic drugs (except aminoglycosides) and could be of
major value in the treatment of intoxications. On the oth-
er hand, drug monitoring and possible adjustments are
necessary during Betasorb hemoperfusion to maintain
the therapeutic ranges of the drugs in blood.
Copyright © 2002 S. Karger AG, Basel
Introduction
In chronic hemodialysis, much effort is invested in
improving the long-term morbidity by removal of toxic
substances in the middle molecular weight range (e.g., ß-
microglobulin). These molecules accumulate in chronic
renal failure and are not sufficiently removed by conven-
tional hemodialyzers, either by using diffusion or convec-
tion [1]. Therefore, increasingly sophisticated techniques
for blood purification utilizing high convective rates and/
or adsorption mechanisms are being developed to expand
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the range of substances removed by renal replacement
techniques.
In the intensive care environment renal replacement
therapy is a well-established treatment modality for acute
renal failure. Renal failure is frequently seen in multiple
organ failure syndrome caused by the systemic inflamma-
tory response syndrome. Cytokines acting as protagonists
in this syndrome have molecular weights in the middle-
molecular weight range. A growing body of evidence sug-
gests a possible beneficial role of removal of middle
molecular weight substances in addition to uremic toxins
in the septic syndrome [2].
Finally, further refinement of blood purification tech-
niques relying on sorbent devices could conceivably have
a major impact on detoxification therapy in exogenous
intoxications (including poisons and drugs). Hemoperfu-
sion techniques using charcoal cartridges are used in only
very selected cases, mostly because of cost and poor
hemocompatibility of the sorbent material, leading to
platelet drop and leukopenia [3]. Increasing charcoal bio-
compatibility by coating leads to a significant loss of
adsorbing capacity, rendering charcoal hemoperfusion a
modality of limited usefulness. Through the availability
of new synthetic polymers with remarkable adsorption
capacity in addition to excellent biocompatibility, the role
of hemoperfusion in the treatment of intoxications possi-
bly will have to be revised. Nevertheless, since adsorption
is not selective with resins and other sorbents, unwanted
losses of beneficial substances or active drugs may occur
during treatment. In this view, it is essential to define the
characteristics of a given sorbent in terms of the adsorp-
tion capacity for drugs. This approach will define the pos-
sible indications in the case of intoxication and overdose,
but also the required prescriptive adjustments in the case
of a renal replacement treatment carried out with the sor-
bent.
We studied a new hemoperfusion cartridge (Betasorb®;
Renal Tech) which has been designed for high-efficiency
removal of substances in the middle molecular weight
range like ß2-microglobulin [4] and cytokines [5]. Due to
the unpredictable nature of adsorption, we expected this
sorbent device to have a high removal capability concern-
ing drugs. Excellent hemocompatibility of the Betasorb
cartridge has been shown in earlier studies [6].
The aim of this in vitro-study was to evaluate the
adsorption capacity in whole blood for several commonly
employed drugs. This serves the purpose of providing
pharmacokinetic data as part of the preclinical evaluation
as well as delineating a possible role for the cartridge in
intoxication treatment.
Materials and Methods
Experimental Setup
The investigation was performed within a set of experiments
examining the adsorptive capacity of drugs by the Betasorb device
applied to uremic blood. Uremic blood was produced in vitro by
mixing concentrated ultrafiltrate from a chronic dialysis patient with
erythrocyte concentrates donated by healthy volunteers. The experi-
ment was performed twice in an identical fashion, but using ultrafil-
trate of 2 different patients.
About 40 liters of ultrafiltrate derived from one hemofiltration
session was used. Subsequently, this amount was recirculated in an in
vitro circuit utilizing a low-flux polysulfone hemofilter (Fresenius
F8, FMC) until about 1,200 ml concentrated fluid was obtained.
Assuming a sieving coefficient of 0.5 of the hemofiltration mem-
brane used in the patient and a sieving coefficient of 0.05 of the low-
flux hemofilter, the final product was expected to be isotonic to plas-
ma water but containing middle molecules at a concentration similar
to that of the uremic plasma at the beginning of a hemodialysis ses-
sion. We confirmed this in a previous experiment [6]. Then a portion
of ultrafiltrate was mixed with two bags of concentrated erythrocytes
to obtain a whole amount of reconstituted blood of 1,200 ml with a
hematocrit of about 30%. This amount was divided into two aliquots
of 600 ml each, to which the drugs to be studied were added imme-
diately before the experiment (fig. 1).
The blood was circulated in an in vitro hemoperfusion circuit for
120 min at a set flow rate of 250 ml/min on a hemodialyzer machine.
Adequate mixing in the blood reservoir was ensured by careful posi-
tioning of arterial and venous lines. Pre- and postcartridge pressures
were measured continuously (fig. 2). A 100-gram Betasorb pilot car-
tridge was used for the experiments.
Blood samples for determination of drug levels were drawn at the
sampling ports placed before and after the cartridge at 0, 5, 15, 30,
60, 90, and 120 min from the start of the experiment.
Instantaneous removal was measured by the arteriovenous differ-
ence multiplied by the flow; cumulative removal was calculated by
the reservoir concentration of the specific drug at the beginning and
at the end of the experiment corrected by variations in the reservoir
volume due to blood samples. Progressive changes in the reservoir
concentration were monitored by the concentration in the arterial
line at different times of the experiments. Each experiment was per-
formed twice except for tacrolimus.
Laboratory Methods
The drug levels were determined by the following methods: car-
bamazepine, phenytoin, phenobarbital, and theophylline by particle-
enhanced turbidimetric inhibition immunoassay (instrument Di-
mension RxL; Dade-Behring); digoxin and cyclosporine A by immu-
noassay (instrument Dimension RxL; Dade-Behring); valproic acid
by enzyme-monitored immunoassay (instrument ACA; Dade-Beh-
ring); amikacin, gentamicin, netilmicin, teicoplanin, tobramycin,
and vancomycin by fluorescence polarization immunoassay (instru-
ment TDx; Abbott), and tacrolimus by microparticle enzyme immu-
noassay (instrument Imx; Abbott). The formulas used for calcula-
tions of the kinetic parameters are given in the appendix.
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Group 1: Amikacin, Gentamicin, Netilmicin
                Teicoplanin, Tobramycin, Vancomycin
Group 2:     Carbamazepine, Digoxin, Phenytoin,
Phenobarbital, Theophylline, Valproic
Acid, Cyclosporine, Tacrolimus.
Blood Bag
Blood Bag
Spent UF from
hemofiltration
Uremic
Blood
1,200 cm3
Fig. 1. The process of obtaining uremic blood starts from concen-
trated ultrafiltrate obtained from patients undergoing hemofiltration
and normal red cells. The mixture simulates the composition of ure-
mic blood. The batch is then split into two aliquots that are injected
with the drugs studied.
Fig. 2. Schematic representation of the in vitro circuit utilized for the
study. P = Pump; S1 and S2 = sampling ports.
Reservoir
Blood
P
S1
Betasorb
S2
Drugs
Pressure Pressure
1
2
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Table 1. Time course of plasma levels according to sampling site
Time
min
Amikacin Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
Gentamicin Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
Tobramycin Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
Netilmicin Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
a
0 520 97 153 26.2 135 21.6 180 24.3
15 493 472 85 83 138 127 19.1 18.7 125 117 16.7 16.4 149 138 15.6 15.3
30 497 478 84 85 138 121 18.6 18.4 117 108 16.9 16.5 146 144 15.2 15.5
60 493 472 84 85 136 132 17.6 17.6 113 113 17.6 17.1 146 142 14.7 15
120 496 473 83 84 129 128 17.0 16.8 111 119 17.4 17.8 147 149 13.8 14
Time
min
Vancomycin Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
Teicoplanin Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
Digoxin ng/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
b
0 1,048 221 179 165 3,900 6,8
15 474 414 42.7 35.8 78 66 25 6.5 358 86 2.4 1.4
30 350 314 15.8 8.9 59 55 2.6 0.7 90 52 0.8 0.5
60 218 205 !0.01 !0.01 36 29 !0.01 !0.01 29 22 0.2 0.1
120 137 148 !0.01 !0.01 19 21 !0.01 !0.01 16 13 !0.05 !0.05
Time
min
Cyclosporine ng/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
Theophylline Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
Tacrolimus ng/ml
experiment I
arterial
site
venous
site
c
0 396 604 32.4 34.4 84.3
15 338 312 380 386 10.2 9.0 12.0 10.6 21.5 21
30 310 277 347 340 9.8 9.6 9.7 9.6 21.4 19.5
60 318 291 369 362 9.7 9.5 8.5 8.2 20.8 20
120 233 217 306 315 9.4 9.2 8.9 8.6 18.6 21.1
Time
min
Valproic acid Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
Phenobarbital Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
Carbamazepine Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
Phenytoin Ìg/ml
experiment I
arterial
site
venous
site
experiment II
arterial
site
venous
site
d
0 105.7 123.7 27.7 61.4 9.6 12.3 16.3 23.3
15 33.1 24.4 45.3 38.7 2.5 1.3 9.9 7.7 0.5 !0.5 1.4 0.6 1.8 1 3.5 2.4
30 25.2 23 36.9 34 1.3 0.8 4.4 4.1 !0.5 !0.5 0.8 0.6 0.9 0.9 1.7 1.2
60 21.2 28.4 28.6 29.8 1.2 0.6 4 3.4 !0.5 !0.5 !0.5 !0.5 !0.5 !0.5 !0.5 !0.5
120 20.6 17.3 26.7 27.6 0.5 0.5 2.3 2 !0.5 !0.5 !0.5 !0.5 !0.5 !0.5 !0.5 !0.5
Results
All experiments were performed without major inter-
ruptions or technical problems. In detail, the end-to-end
pressure drop in the cartridge remained stable over time,
indicating a constant patency of the unit and the absence
of major changes in the priming volume of the sorbent
cartridge (fig. 3). The data are reported in table 1. The
respective drug concentrations are listed with regard to
the relative time points of sampling and sampling site (ar-
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terial or venous, i.e., before or after the hemoperfusion
cartridge). During the experiment, the blood pH value
remained stable at 6.8. The cartridge performed very well
with respect to hemocompatibility (table 2), showing no
changes in platelet and leukocyte counts. As depicted in
figures 4 and 5, there were no visible signs of blood stasis
during and at the end of the hemoperfusion session as well
as after rinsing the cartridge with saline.
Aminoglycosides were removed to a marginal degree.
Figure 6 shows the percentages by which the plasma levels
declined over time, the arterial value at time point zero
being set at 100%. The plasma levels of amikacin de-
creased by 4.6 and 14.4%. Practically all removal took
place within the first 15 min. Over the following 90 min,
adsorption and desorption from the membrane seemed to
be in equilibrium, as a reduction in plasma levels by pas-
sage over the cartridge still was measurable at specific
time points, but not overall.
Netilmicin, tobramycin, and gentamicin (fig. 6, 7)
showed a similar behavior, with maximal removal also
within the first 15 min. With lower initial plasma drug
levels, the relative amount of removal was higher (up to
42% with netilmicin). Therefore, the relative removal
rates generally were larger in the second set of experi-
ments, where the initial drug concentrations were lower
because of comparable absolute amounts of removal.
Vancomycin, teicoplanin, digoxin, carbamazepine,
phenytoin, and phenobarbital were practically completely
Fig. 3. Pressure behaviours at the inlet and outlet of the cartridge
during the study. The constant value indicates that no clotting or loss
of surface area occurred during the study.
200
175
150
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100
75
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25
0
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Outlet
15 30 600 90
Qb = 250 ml/min
Fig. 4. Pictures of the cartridge at different times during the study. It is evident that a homogeneous distribution of
blood is present for the entire duration of the experiment.
5 min after start 60 min after start 90 min after start 
Table 2. Hemocompatibility: standard blood values at start and end of the experiments
Time
min
RBC 106/mm3
exp I exp II
Hct, %
exp I exp II
WBC 103/mm3
exp I exp II
Platelets G/l
exp I exp II
Albumin, g/l
exp I exp II
0 2.74 3.56 25.9 32.3 1.22 1.02 34 7 0.4 0.8
120 2.71 3.27 25.7 29.6 1.04 0.51 24 1 0.2 0.5
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Fig. 5. Pictures of the cartridge after the experiment. The sorbent
appears clean and well rinsed confirming the absence of blood residu-
als.
Cartr. 105 at the end Venous port after Rinse 
Cartr. 105 after Rinse Detailed image after
Fig. 6. Percent decrease in blood concentration of gentamicin and
amikacin over time.
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Fig. 7. Percent decrease in blood concentration of netilmycin and
tobramycin over time.
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removed, predominantly within 5–15 min (fig. 8, 9).
Slight but insignificant amounts of desorption were ap-
parent only with vancomycin between time points 60 and
120 min (the values after the filter passage being slightly
higher than those before). Theophylline, tacrolimus
(fig. 10), and valproic acid (fig. 9) were significantly ad-
sorbed to an extent of 72–84%. Tacrolimus and valproic
acid showed minimal desorption after 60 min. Cyclospo-
rine (fig. 10) showed intermediate removal amounts of 45
and 48%. In the first experiment, there was ongoing
adsorption of cyclosporine over 120 min, whereas in the
second set a slight desorption could be demonstrated after
60 min. The cumulative removal for all drugs examined is
shown in table 3.
Discussion
Chronic hemodialysis patients continue to have a sig-
nificant morbidity despite considerable improvement in
filter and dialysis techniques with high-efficiency removal
of low molecular weight uremic toxins [1]. Over the last
years more and more (definitive and probable) uremic
toxins in the middle molecular weight range have been
identified. A search for means to effectively remove these
toxins has been launched. As sorbent materials with a
much higher biocompatibility as compared with charcoal
have become available, a renewed interest in blood purifi-
cation modalities using sorbents has developed [6]. Apart
from employment in chronic hemodialysis, a further ex-
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Fig. 8. Percent decrease in blood concentration of vancomycin, tei-
coplanin and digoxin over time.
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Vancomycin II
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Digoxin I
Digoxin II
Fig. 9. Percent decrease in blood concentration of phenobarbital,
phenytoin, carbamazepine and vaproic acid over time.
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80
Fig. 10. Percent decrease in blood concentration of theophylline,
tacrolimus and cyclosporine over time.
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citing indication for sorbent hemoperfusion undergoing
active investigation is in patients with systemic inflam-
matory response syndrome for mediator removal, e.g.,
cytokines [2]. Furthermore, a number of currently used
drugs may sometimes be observed at toxic concentrations
(e.g., theophylline, digoxin, and valproic acid) due to acci-
dental overdose or to other conditions. These are major
challenges for detoxification therapies, as protein binding
and/or hydrophobicity of the molecules often preclude
effective removal by forced diuresis or hemofiltration/
dialysis modalities. In severe intoxications charcoal he-
moperfusion has been a historical standard treatment.
However, its application has been limited by low biocom-
patibility (when uncoated) or less-than-optimal adsorp-
tive capacity (when made more biocompatible by coat-
ing). Adsorbents of any type – excluding antibody-coated
membranes for immune system specific removal – char-
acteristically behave nonspecifically in their adsorptive
process. Therefore, studies are important to evaluate the
impact of their use on the plasma levels of therapeutic
drugs either for detoxification purposes or for optimiza-
tion of drug prescription.
In this study, we evaluated the performance of the
hemoperfusion cartridge Betasorb. This device is a specif-
ically developed adsorption column for removal of ß2-
microglobulin (11.8 kD). It contains hydrated, hyper-
cross-linked polystyrene resin beads (designed to remove
molecules between 4 and 20 kD; bead size 400–1,000 Ìm)
with an enhanced proportion of mesopores in the range of
2–20 nm. The cartridge shows an excellent hemocompati-
bility [6, 7] through coating by hydrophilic substitution of
vinyl chains [8]. The flow-dynamic pattern has been char-
acterized in vitro [9]. With ex vivo-testing in whole blood,
the plasma levels of ß2-microglobulin, tumor necrosis fac-
tor alpha, and interleukin 1 beta could be significantly
reduced [5, 7]. In dogs with chronic renal failure, the plas-
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Table 3. Total mass removal over 120 min
Total amount
at start removed
Amikacin, mg 624 128
Gentamicin, mg 183.6 54.6
Tobramycin, mg 162 51
Netilmicin, mg 216 69
Vancomycin, mg 1,258 1,121
Teicoplanin, mg 198 198
Digoxin, Ìg 4,680 4,664
Cyclosporine, Ìg 725 434
Theophylline, mg 412.8 32.8
Tacrolimus, Ìg 101.2 83.5
Valproic acid, mg 148 123
Phenobarbital, mg 73.6 71.5
Carbamazepine, mg 14.8 14.8
Phenytoin, mg 28 28
ma ß2-microglobulin levels were reduced in excess of 70%
per session of combined hemodialysis and Betasorb he-
moperfusion [4]. First clinical experience demonstrated a
decrease in the plasma concentrations of ß2-microglobu-
lin by 79 and 69% [10, 11].
We now have characterized the adsorptive perfor-
mance of this device with regard to 14 commonly used
drugs. The drugs examined differ in molecular weight
(range 236–1,993 Da), protein binding (range 0–95%), as
well as solubility (very water soluble to insoluble). As the
blood preparation examined contained a high number of
drugs, possible chemical interactions could be of concern.
To our knowledge, no such interactions in whole blood
have been described for the drugs we used in our experi-
ments.
The different drugs studied encompass a wide range of
medications commonly prescribed in internal medicine
and the intensive care setting. They are potent drugs; con-
sequently, their plasma levels often need to be kept in a
narrow therapeutic range. Therefore, it is vital to know to
what extent plasma levels are influenced by hemoperfu-
sion. On the one hand, hemoperfusion performed for a
reason not related to drug intoxication could lead to dan-
gerous lowering of the plasma levels of the drug. On the
other hand, obviously a high absorptive capacity for toxic
drugs would open a wide avenue for therapeutic use in
detoxification.
All aminoglycosides tested in our study were poorly
adsorbed. The use of the Betasorb device probably should
be of no significance concerning their dosage. The other
drugs studied were removed to a significant degree.
Hence, additional dosages may be necessary to be given
and strict serum drug level monitoring performed when
using the Betasorb device.
Concerning intoxications with digoxin, carbamaze-
pine, teicoplanin, vancomycin, valproic acid, phenytoin,
phenobarbital, and theophylline, Betasorb hemoperfu-
sion demonstrates a potentially important role in detoxifi-
cation. Important to note is the possibility of later desorp-
tion of the drug from the membrane. It would seem pru-
dent to limit hemoperfusion in drug intoxication to a peri-
od of 1 h or to increase the size of the cartridge employed
for this purpose. In interpreting these results, it should be
kept in mind that only a prototype device containing
100 g sorbent was used. For clinical implementation, the
amount of sorbent per cartridge will certainly be in-
creased by the manufacturer.
Desorption from the membrane after establishment of
a concentration, equilibrium with plasma is a known pro-
cess which depends on the physicochemical characteris-
tics of the adsorption. Potentially relevant desorption
should be detectable by a pre-post cartridge gradient with
a higher drug concentration after passage of the filter.
This was the case, to a minimal extent, for valproic acid,
teicoplanin, vancomycin, netilmicin, and tobramycin
without clinically significant impact on the plasma levels.
Nevertheless, with very high plasma drug levels as en-
countered in intoxications, desorption should be a func-
tion of absolute adsorbing capacity of the cartridge. The
possibility that desorption then takes place at higher plas-
ma levels cannot be excluded by our data.
Tacrolimus is known to accumulate in erythrocytes,
and equilibrium dynamics over the erythrocyte mem-
brane have to be considered. The same is valid for cyclo-
sporine. In our study, both drugs showed the lowest
removal rates by Betasorb as compared with other drugs.
Slow transport across the erythrocyte membrane may be
the cause. On the other hand, we could demonstrate a
slight desorption starting after 60 min of perfusion which
argues for saturation of the cartridge with only moderately
strong affinity as the underlying mechanism. For clari-
fying this issue, further investigations including a pro-
longed perfusion time have to be conducted.
Our results compare favorably with sorbent devices in
use up to now, like charcoal [3] and Amberlite resins [13].
Notably, the Betasorb cartridge, as compared with older
sorbents, has a superior biocompatibility [14]. Of the
more recently developed sorbent devices [reviewed in 15],
only the microsphere detoxification system has under-
gone in vitro testing with respect to drugs. Only data on
388 Blood Purif 2002;20:380–388 Reiter et al.
phenobarbital removal are available, showing significant
effects [16].
In conclusion, in this study, we investigated in an in
vitro hemoperfusion circuit the drug-adsorbing capacity
of the new synthetic sorbent device Betasorb. The remov-
al kinetics are also described. Excluding aminoglycosides,
we could demonstrate an impressive removal of a number
of therapeutic drugs relevant in current medical and
intensive care practice. The data are relevant for drug dos-
ing during hemoperfusion. Modern sorbent technology
due to its excellent biocompatibility and high adsorbent
capacity has the potential to become the first-line treat-
ment modality in a number of severe intoxications by
medical drugs.
Appendix
Arterial venous difference (¢) Concart – Concven
Removal rate (Concart – Concven) ! Qb
Cumulative mass removal (at t) (Concres ! V)base – (Concres ! V)t
Clearance [(Concart – Concven)/Concart] ! Qb
where Concart = concentration of the solute before the cartridge,
Concven = concentration of the solute after the cartridge, Concres =
concentration of the solute in the reservoir, V = volume of blood in
the reservoir, Qb = effective blood flow.
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